Edition:
United States

Merck & Co Inc (MRK.N)

MRK.N on New York Stock Exchange

62.98USD
12:29pm EDT
Change (% chg)

$0.25 (+0.40%)
Prev Close
$62.73
Open
$62.82
Day's High
$63.10
Day's Low
$62.49
Volume
723,529
Avg. Vol
2,876,429
52-wk High
$64.00
52-wk Low
$47.97

Latest Key Developments (Source: Significant Developments)

Merck provides regulatory update on Biologics application
Thursday, 21 Jul 2016 04:30pm EDT 

Merck & Co Inc : Fda has requested submission of new data and analyses from modify I and modify II clinical trials previously submitted . Merck provides regulatory update on Biologics licensing application for investigational agent Bezlotoxumab . Merck provides regulatory update on Biologics licensing application for investigational agent Bezlotoxumab .New Bezlotoxumab PDUFA date will be Oct. 23, 2016..  Full Article

Merck's Healthcare invests majority stake in Staywell
Monday, 11 Jul 2016 07:00am EDT 

Merck & Co Inc : Merck's Healthcare Services & Solutions invests in majority stake in Staywell .Terms of transaction were not disclosed..  Full Article

Merck Animal Health to buy controlling interest in Vallée S.A
Friday, 1 Jul 2016 12:05pm EDT 

Merck Animal Health: Will acquire approximately 93 pct of shares of Vallée S.A. at closing, in exchange for a payment of $400 mln .To acquire a controlling interest in Vallée S.A.  Full Article

Merck, Premier Inc collaborate to improve care for osteoporosis patients
Thursday, 30 Jun 2016 09:28am EDT 

Merck & Co In : Merck And Premier Inc collaborate to prevent fractures for osteoporosis patients .Financial terms of agreements were not disclosed.  Full Article

Merck's Keytruda shows superior progression-free, overall survival in lung cancer patients
Thursday, 16 Jun 2016 06:45am EDT 

Merck & Co Inc : Merck's keytruda® (pembrolizumab) demonstrates superior progression-free and overall survival compared to chemotherapy as first-line treatment in patients with advanced non-small cell lung cancer . Keynote-024 trial met its primary endpoint . Safety profile of keytruda in this trial was consistent with that observed in previously reported studies in patients with advanced nsclc . Based on these results, an independent data monitoring committee (dmc) has recommended that trial be stopped . Independent data monitoring committee recommended patients receiving chemotherapy in keynote-024 be offered opportunity to receive keytruda. .Keytruda was superior compared to chemotherapy for primary endpoint of progression-free survival, and secondary endpoint of overall survival.  Full Article

Merck to acquire Afferent Pharmaceuticals
Thursday, 9 Jun 2016 05:07pm EDT 

Merck & Co Inc : Merck to acquire Afferent Pharmaceuticals . Signed a definitive agreement under which Merck will acquire Afferent Pharmaceuticals . Under terms, Merck, through unit, to acquire outstanding stock of Afferent for an upfront payment of $500 million in cash .Afferent shareholders will be eligible to receive a total of up to an additional $750 million associated with attainment of certain milestones.  Full Article

Merck Global Health Innovation Fund hikes stake in OpGen to 37.5 pct from 11.8 pct
Friday, 27 May 2016 04:01pm EDT 

Merck Global Health Innovation Fund, Llc : Merck Global Health Innovation Fund, Llc reports a stake of 37.5 percent in Opgen Inc as of May 19, 2015 .Merck Global Health Innovation Fund, Llc had previously reported a 11.80 pct stake in Opgen Inc - SEC filing.  Full Article

Merck sets quarterly dividend of 46 cents per share
Tuesday, 24 May 2016 02:35pm EDT 

Merck & Co Inc :Sets quarterly dividend of $0.46 per share.  Full Article

Merck names Sanat Chattopadhyay president of Merck Manufacturing Division
Monday, 7 Mar 2016 04:30pm EST 

Merck MRK.N:Names Sanat Chattopadhyay president of Merck Manufacturing Division; will succeed Willie Deese who will retire.Deese will retire on June 1, 2016.Says Chattopadhyay joined Merck in 2009 and currently serves as senior vice president of global Manufacturing Operations.  Full Article

Merck & Co Inc's investigational once-daily formulation of ISENTRESS meets primary and secondary endpoints in pivotal phase 3 study
Monday, 22 Feb 2016 08:00am EST 

Merck & Co Inc:Says its investigational once-daily formulation of ISENTRESS meets primary and secondary endpoints in pivotal phase 3 study.Says 1200 mg raltegravir was statistically non-inferior to the marketed formulation approved dose.  Full Article

BRIEF-Biothera Pharmaceuticals expands relationship with Merck

* Biothera pharmaceuticals expands relationship with Merck, enters collaboration for combination cancer immunotherapy trials in multiple indications Source text for Eikon: Further company coverage: